{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:47:56Z","timestamp":1782197276896,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41397-026-00417-1","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T10:56:04Z","timestamp":1779706564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of encorafenib in untreated BRAF V600E-mutant metastatic colorectal cancer in China"],"prefix":"10.1038","volume":"26","author":[{"given":"Shaohong","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangzhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8901-5281","authenticated-orcid":false,"given":"Xiuhua","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4787-2506","authenticated-orcid":false,"given":"Xiongwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"417_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000543921","volume":"106","author":"T Matsuda","year":"2025","unstructured":"Matsuda T, Fujimoto A, Igarashi Y. Colorectal cancer: epidemiology, risk factors, and public health strategies. Digestion. 2025;106:91\u201399.","journal-title":"Digestion"},{"key":"417_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"417_CR3","first-page":"1","volume":"16","author":"RM Guerrero","year":"2022","unstructured":"Guerrero RM, Labajos VA, Ballena SL, Macha CA, Lezama MS, Roman CP, et al. Targeting BRAF V600E in metastatic colorectal cancer: where are we today? Ecancermedicalscience. 2022;16:1\u201318.","journal-title":"Ecancermedicalscience"},{"key":"417_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3390\/cancers13010137","volume":"13","author":"G Mauri","year":"2021","unstructured":"Mauri G, Bonazzina E, Amatu A, Tosi F, Bencardino K, Gori V, et al. The evolutionary landscape of treatment for BRAFV600E mutant metastatic colorectal cancer. Cancers. 2021;13:137\u201351.","journal-title":"Cancers"},{"key":"417_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21239001","volume":"21","author":"A Djanani","year":"2020","unstructured":"Djanani A, Eller S, \u00d6fner D, Troppmair J, Maglione M. The role of BRAF in metastatic colorectal carcinoma\u2013past, present, and future. Int J Mol Sci. 2020;21:1\u201321.","journal-title":"Int J Mol Sci"},{"key":"417_CR6","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.annonc.2021.03.206","volume":"32","author":"A Grothey","year":"2021","unstructured":"Grothey A, Fakih M, Tabernero J. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. Ann Oncol. 2021;32:959\u201367.","journal-title":"Ann Oncol"},{"key":"417_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.20.02088","volume":"39","author":"J Tabernero","year":"2021","unstructured":"Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E\u2013mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON Study. J Clin Oncol. 2021;39:273\u201384.","journal-title":"J Clin Oncol"},{"key":"417_CR8","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","volume":"392","author":"E Elez","year":"2025","unstructured":"Elez E, Yoshino T, Shen L, Lonardi S, Van Cutsem E, Eng C, et al. Encorafenib, cetuximab, and mFOLFOX6 in BRAF -mutated colorectal cancer. N Engl J Med. 2025;392:2425\u201337.","journal-title":"N Engl J Med"},{"key":"417_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamanetworkopen.2020.33441","volume":"4","author":"KK Patel","year":"2021","unstructured":"Patel KK, Stein S, Lacy J, O\u2019Hara M, Huntington SF. Evaluation of the cost-effectiveness of doublet therapy in metastatic BRAF variant colorectal cancer. JAMA Netw Open. 2021;4:1\u201310.","journal-title":"JAMA Netw Open"},{"key":"417_CR10","first-page":"221","volume":"46","author":"RS Zheng","year":"2024","unstructured":"Zheng RS, Chen R, Han BF, Wang SM, Li L, Sun K, et al. Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi. 2024;46:221\u201331.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"417_CR11","first-page":"1","volume":"13","author":"Y Li","year":"2024","unstructured":"Li Y, Hu M, Zhang Z, Chu M, Xu R, Liu L, et al. Cost-effectiveness analysis of continuing bevacizumab plus chemotherapy versus chemotherapy alone after first progression of metastatic colorectal cancer. Cancer Med. 2024;13:1\u201310.","journal-title":"Cancer Med"},{"key":"417_CR12","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12876-025-03867-2","volume":"25","author":"WJ Liu","year":"2025","unstructured":"Liu WJ, Fang YT, Zhang C, Xiang MD, Qi LJ, Su AJ, et al. Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma. BMC Gastroenterol. 2025;25:266\u201378.","journal-title":"BMC Gastroenterol"},{"key":"417_CR13","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1177\/0272989X19873661","volume":"39","author":"B Kearns","year":"2019","unstructured":"Kearns B, Stevenson MD, Triantafyllopoulos K, Manca A. Generalized linear models for flexible parametric modeling of the hazard function. Med Decis Mak Int J Soc Med Decis Mak. 2019;39:867\u201378.","journal-title":"Med Decis Mak Int J Soc Med Decis Mak"},{"key":"417_CR14","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s11096-025-01865-8","volume":"47","author":"Y Wu","year":"2025","unstructured":"Wu Y, Tao L, Liu C, Wang F, Sun S. Cost-effectiveness analysis of PD-L1 testing associated with pembrolizumab for first-line treatment of advanced non-small cell lung cancer in China. Int J Clin Pharm. 2025;47:737\u201346.","journal-title":"Int J Clin Pharm"},{"key":"417_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpubh.2024.1465898","volume":"12","author":"LZ Huang","year":"2024","unstructured":"Huang LZ, Chen YQ, Gu HY, Chen Y. Cost-effectiveness analysis of trifluridine\/tipiracil combined with bevacizumab vs. monotherapy for third-line treatment of colorectal cancer. Front Public Health. 2024;12:1\u201310.","journal-title":"Front Public Health"},{"key":"417_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-023-10037-1","volume":"23","author":"C Zhu","year":"2023","unstructured":"Zhu C, Han G, Wu B. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system. BMC Health Serv Res. 2023;23:1\u201313.","journal-title":"BMC Health Serv Res"},{"key":"417_CR17","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s11096-024-01721-1","volume":"46","author":"Z Huang","year":"2024","unstructured":"Huang Z, Zhou L, Zheng H, Zhan M. Cost-effectiveness analysis of fruquintinib in Chinese patients with refractory metastatic colorectal cancer. Int J Clin Pharm. 2024;46:872\u201380.","journal-title":"Int J Clin Pharm"},{"key":"417_CR18","unstructured":"China Foreign Exchange Trade System: Exchange rate of the RMB. https:\/\/www.chinamoney.com.cn\/chinese\/bkccpr\/ (accessed 22 May 2026)."},{"key":"417_CR19","unstructured":"National Bureau of Statistics of China: China Statistical Yearbook 2025. https:\/\/www.stats.gov.cn\/english\/Statisticaldata\/yearbook\/ (accessed 22 May 2026)."},{"key":"417_CR20","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1200\/JCO.2016.67.4846","volume":"34","author":"C Guenancia","year":"2016","unstructured":"Guenancia C, Lefebvre A, Cardinale D, Yu AF, Ladoire S, Ghiringhelli F, et al. Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:3157\u201365.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"417_CR21","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/ijc.35432","volume":"157","author":"JA Garc\u00eda-Saenz","year":"2025","unstructured":"Garc\u00eda-Saenz JA, Spera G, Poll\u00e1n M, Bermejo B, Ruiz-Borrego M, Chan A, et al. Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: a pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies. Int J Cancer. 2025;157:709\u201321.","journal-title":"Int J Cancer"},{"key":"417_CR22","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1093\/annonc\/mdw315","volume":"27","author":"J Furlanetto","year":"2016","unstructured":"Furlanetto J, Eiermann W, Marm\u00e9 F, Reimer T, Reinisch M, Schmatloch S, et al. Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study. Ann Oncol Off J Eur Soc Med Oncol. 2016;27:2053\u20139.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"417_CR23","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1056\/NEJMoa2404139","volume":"391","author":"GV Long","year":"2024","unstructured":"Long GV, Hauschild A, Santinami M, Kirkwood JM, Atkinson V, Mandala M, et al. Final results for adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med. 2024;391:1709\u201320.","journal-title":"N Engl J Med"},{"key":"417_CR24","first-page":"1","volume":"204","author":"D Schadendorf","year":"2024","unstructured":"Schadendorf D, Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, et al. COLUMBUS 7-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E\/K-mutant melanoma. Eur J Cancer Oxf Engl 1990. 2024;204:1\u20138.","journal-title":"Eur J Cancer Oxf Engl 1990"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00417-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00417-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00417-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:12:08Z","timestamp":1782195128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00417-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["417"],"URL":"https:\/\/doi.org\/10.1038\/s41397-026-00417-1","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"We confirmed that all methods were performed in accordance with the relevant guidelines and regulations. This economic analysis was based on published literature and modeling techniques. No ethical approval and informed consent were needed for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"24"}}